These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 25028401)

  • 1. Programmed cell death 1-directed immunotherapy for enhancing T-cell function.
    Araki K; Youngblood B; Ahmed R
    Cold Spring Harb Symp Quant Biol; 2013; 78():239-47. PubMed ID: 25028401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming T cell exhaustion in infection and cancer.
    Pauken KE; Wherry EJ
    Trends Immunol; 2015 Apr; 36(4):265-76. PubMed ID: 25797516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions.
    Hashimoto M; Kamphorst AO; Im SJ; Kissick HT; Pillai RN; Ramalingam SS; Araki K; Ahmed R
    Annu Rev Med; 2018 Jan; 69():301-318. PubMed ID: 29414259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversing T-cell Dysfunction and Exhaustion in Cancer.
    Zarour HM
    Clin Cancer Res; 2016 Apr; 22(8):1856-64. PubMed ID: 27084739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoring function in exhausted CD8 T cells during chronic viral infection.
    Barber DL; Wherry EJ; Masopust D; Zhu B; Allison JP; Sharpe AH; Freeman GJ; Ahmed R
    Nature; 2006 Feb; 439(7077):682-7. PubMed ID: 16382236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer.
    McLane LM; Abdel-Hakeem MS; Wherry EJ
    Annu Rev Immunol; 2019 Apr; 37():457-495. PubMed ID: 30676822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment.
    Blake SJ; Ching AL; Kenna TJ; Galea R; Large J; Yagita H; Steptoe RJ
    PLoS One; 2015; 10(3):e0119483. PubMed ID: 25741704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of programmed death receptor-1 signaling restores expression of mostly proinflammatory cytokines in anergic cytomegalovirus-specific T cells.
    Dirks J; Egli A; Sester U; Sester M; Hirsch HH
    Transpl Infect Dis; 2013 Feb; 15(1):79-89. PubMed ID: 23176118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment.
    Wang Q; Wu X
    Int Immunopharmacol; 2017 May; 46():210-219. PubMed ID: 28324831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Regulation of T-cell immune exhaustion and cancer immunotherapy].
    Eikawa S; Udono H
    Gan To Kagaku Ryoho; 2014 Sep; 41(9):1066-70. PubMed ID: 25248889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-PD-1 antibody: basics and clinical application].
    Tanaka Y; Okamura H
    Gan To Kagaku Ryoho; 2013 Sep; 40(9):1145-9. PubMed ID: 24047772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
    Kline J; Gajewski TF
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1354-9. PubMed ID: 21154117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orchestrating immune check-point blockade for cancer immunotherapy in combinations.
    Perez-Gracia JL; Labiano S; Rodriguez-Ruiz ME; Sanmamed MF; Melero I
    Curr Opin Immunol; 2014 Apr; 27():89-97. PubMed ID: 24485523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD8 T-cell heterogeneity during T-cell exhaustion and PD-1-targeted immunotherapy.
    Ando S; Araki K
    Int Immunol; 2022 Oct; 34(11):571-577. PubMed ID: 35901837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-GITR agonist therapy intrinsically enhances CD8 T cell responses to chronic lymphocytic choriomeningitis virus (LCMV), thereby circumventing LCMV-induced downregulation of costimulatory GITR ligand on APC.
    Clouthier DL; Zhou AC; Watts TH
    J Immunol; 2014 Nov; 193(10):5033-43. PubMed ID: 25281716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation.
    Ghoneim HE; Fan Y; Moustaki A; Abdelsamed HA; Dash P; Dogra P; Carter R; Awad W; Neale G; Thomas PG; Youngblood B
    Cell; 2017 Jun; 170(1):142-157.e19. PubMed ID: 28648661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
    Evans A; Riva A; Cooksley H; Phillips S; Puranik S; Nathwani A; Brett S; Chokshi S; Naoumov NV
    Hepatology; 2008 Sep; 48(3):759-69. PubMed ID: 18697210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B.
    Zhang Z; Zhang JY; Wherry EJ; Jin B; Xu B; Zou ZS; Zhang SY; Li BS; Wang HF; Wu H; Lau GK; Fu YX; Wang FS
    Gastroenterology; 2008 Jun; 134(7):1938-49, 1949.e1-3. PubMed ID: 18455515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8⁺ T cells.
    Kaiser AD; Schuster K; Gadiot J; Borkner L; Daebritz H; Schmitt C; Andreesen R; Blank C
    Eur J Immunol; 2012 Mar; 42(3):662-71. PubMed ID: 22144176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory signals mediated by programmed death-1 are involved with T-cell function in chronic periodontitis.
    Figueira EA; de Rezende ML; Torres SA; Garlet GP; Lara VS; Santos CF; Avila-Campos MJ; da Silva JS; Campanelli AP
    J Periodontol; 2009 Nov; 80(11):1833-44. PubMed ID: 19905953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.